0IIM Stock Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Esperion Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.15 |
| 52 Week High | US$3.37 |
| 52 Week Low | US$0.71 |
| Beta | 0.82 |
| 1 Month Change | 0.84% |
| 3 Month Change | -32.50% |
| 1 Year Change | 74.90% |
| 3 Year Change | -92.36% |
| 5 Year Change | n/a |
| Change since IPO | -97.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IIM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -34.8% | 3.1% | 1.2% |
| 1Y | 74.9% | -3.1% | -0.3% |
Return vs Industry: 0IIM exceeded the UK Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: 0IIM exceeded the UK Market which returned -0.3% over the past year.
Price Volatility
| 0IIM volatility | |
|---|---|
| 0IIM Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IIM's share price has been volatile over the past 3 months.
Volatility Over Time: 0IIM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 240 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Esperion Therapeutics, Inc. Fundamentals Summary
| 0IIM fundamental statistics | |
|---|---|
| Market cap | US$405.32m |
| Earnings (TTM) | -US$209.25m |
| Revenue (TTM) | US$116.33m |
3.5x
P/S Ratio-1.9x
P/E RatioIs 0IIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IIM income statement (TTM) | |
|---|---|
| Revenue | US$116.33m |
| Cost of Revenue | US$129.37m |
| Gross Profit | -US$13.04m |
| Other Expenses | US$196.21m |
| Earnings | -US$209.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | -11.21% |
| Net Profit Margin | -179.87% |
| Debt/Equity Ratio | -117.9% |
How did 0IIM perform over the long term?
See historical performance and comparison